Study Group: Physicians who Treat Chronic Sinusitis (US)
Council Members in this Study Group: 141
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Marina RaikhelDirector
TORRANCE MEMORIAL MEDICAL CENTER
Marina Raikhel, MD, is an active family practitioner with a particular interest in primary care and ob/gyn focus. She has expertise in the treatment of a wide variety of internal medicine conditions, with special focus on diabetes, hypertension, obesity,...
Adam SchaffnerAssistant Professor of Clinical Plastic Surgery
Georgetown University Medical Center - CCAdam D. Schaffner, MD, FACS, is an Assistant Professor of Clinical Plastic and Reconstructive Surgery, Georgetown University Medical Center. He has previously served as a Clinical Assistant Professor of Otorhinolaryngology at Weill Cornell Medical College...
- Mark Vandewalker
Allergy Specialist and Partner
Allergy & Asthma Consultants Of The Ozarks LtdMark Vandewalker, MD, is an Allergy Specialist at Allergy and Asthma Consultants and he is the Medical Director at Clinical Research of the Ozarks in Missouri. Dr. Vandewalker is board-certified in Pediatric Allergy and has been practicing for almost...
- Mitchell Boxer
Assistant Clinical Professor
Albert Einstein College of MedicineMitchell Boxer, MD, is Director of the Adult Allergy Section at Long Island Jewish Medical Center and Assistant Clinical Professor at Albert Einstein Medical College. He also runs his own private practice. Dr. Boxer completed his fellowship at Northwestern...
Brian KaplanOtolaryngologist
Ear, Nose & Throat AssociatesBrian Kaplan, MD, FACS, is an otolaryngologist at the Ear, Nose & Throat Associates in Baltimore, MD. He also serves as Attending Physician at both the Greater Baltimore Medical Center and Johns Hopkins University. Dr. Kaplan specializes in head and neck...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Another chink in the branded PPI armor
June 23, 2009
Analysis by: Brian Kaplan, Otolaryngologist ,Nycomed receives Marketing Authorization for Pantoprazole 20mg OTC from European Commission | www.pharmanews.eu
With the coming application for OTC status in the U.S. (after the EU) this will be another blow against the branded PPI market. With efficacious OTC options, 3rd party payers will continue to put up obstacles to both branded and BID dosing.
-
FDA Poised to Damage Asthma Pharmacotherapy Advances
December 10, 2008
FDA: Long-Acting Asthma Drugs Increase Asthma Risks | online.wsj.com
The use of long-acting beta-agonists (LABAs) in the treatment of persistent asthma has become one of the most controversial issues of respiratory disease management during this decade. Both salmeterol and formoterol have been shown in numerous clinical trials of asthma to dramatically improve pulmonary function, symptoms scores, and need for rescue medication. However, some long-term safety studies have demonstrated increased risk of severe asthma exacerbations when these LABAs are used as monotherapy without concomitant inhaled steroid therapy. Based on this data, the FDA is considering the withdrawal of LABAs from the US market. I anticipate the FDA will come to their senses and appreciate the significant benefit that combination LABA/ICS therapy has in the vast majority of moderate and severe asthmatics for whom they are appropriately prescribed. In my opinion, cessation of LABA therapy for asthma would return us to asthma mortality rates not seen since the 1990s.
-
Bold Contest for a Daunting Problem
October 27, 2008
WellPoint, X Prize launch $10M health care contest | news.yahoo.com
Most people agree that the healthcare system in the United States is in need of a complete overhaul. Unfortunately, the many competing interests in the current system make such overhaul extremely challenging. This contest certainly provides much incentive for the best and brightest to put forth their ideas on how to improve the system. Overcoming the obstacles to implenting such ideas will potentially be the biggest challenge of all. Therefore, I believe the answer to the question "Will it work?" will only come when the healthcare system reaches the same critical threshold that our financial markets recently met.
-
Evolence: Will this New "Advanced" Collagen Filler Take Hold?
July 8, 2008
FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler | www.investor.jnj.com
Evolence is an injectable filler material that is made by an "advanced collagen GLYMATRIX™ Technology." Collagen has generally fallen out of favor amongst aesthetic physicians due to its short duration of action. Evolence will have to demonstrate that it is superior to the plethora of other injectable filler materials currently available to gain market share. To do so will not only require clinical efficacy, it will also require a tremendous marketing effort to penetrate a market where there is no shortage of injectable filler materials from which to choose.
-
Allergan and Aczone: Likely a Winning Combination
June 26, 2008
Allergan Aquisition of Aczone | agn360.client.shareholder.com
Allergan has a strong infrastructure to support dermatologic and aesthetic products. Aczone, an aqueous topical gel containing 5% dapsone, will be a new product which will help treat patients with acne. "The strength of topical dapsone gel appears to be its high efficacy against inflammatory acne lesions. Both rapid onset of action and tolerability make this agent a potentially nice complement to traditional antimicrobial and comedolytic acne regimens." (Draelos ZD, Carter E, Maloney JM, et al, J Am Acad Dermatol. 2007;56:439.e1-e10.) Based on the study results available, it appears Aczone will provide an additional treatment option which will benefit patients. Given the number of patients afflicted with acne, I believe Allergan will ultimately view this as a favorable acquisition.
Members in this Study Group include these company types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Owner
- Partner
- Physician - Director
- President